Day: January 15, 2023

CLINUVEL Trial Results Show Drug Reduces DNA Damage

CLINUVEL Trial Results Show Drug Reduces DNA Damage

Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) — Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers. The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extreme rates of skin cancers and forces patients to live in the dark. “XP patients are known as ‘children of the moon’ due to their need to avoid any light and sun exposure or risk severe, aggressive skin cancers from an early age,” CLINUVEL’s expert genomic scientist, Dr Jessica Nucci said. “Our first...

Continue reading

Manhattan Streamlines Store Inventory Management

Manhattan Streamlines Store Inventory Management

Expanded RFID capabilities in its store solution improves inventory accuracy, automates store processes and reduces labor costs NEW YORK, Jan. 15, 2023 (GLOBE NEWSWIRE) — Today at the NRF Big Show, Manhattan Associates Inc. (NASDAQ: MANH) unveiled its vision for an RFID-powered store. Manhattan Active® Omni suite has expanded its support of RFID tags for automating and streamlining the inventory counting, receiving, picking, checkout, return and exchange processes. With this new solution, retailers can make more accurate promises, increase conversion rates and maximize inventory exposure for selling. Retailers are increasingly depending on their stores to fulfill both in-store and online orders. However, their ability to do so is often hindered by poor store inventory accuracy, which often falls below 70%. In fact, a recent Manhattan...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.